• In Situ tRNA Synthesis Sustains Cell-Free Translation

  2026-10-03

  Li, Baranwal, and Maerkl report a strategy for producing all 21 translation-relevant tRNAs directly within a recombinant PURE cell-free system. The study links in situ tRNA synthesis to sustained, steady-state protein expression in microfluidic chemostats, providing an important step toward self-regenerating biochemical systems while leaving broader questions about full system autonomy unresolved.

• DAPI (hydrochloride) in Translational Organoids

  2026-10-01

  DAPI (hydrochloride) is more than a nuclear counterstain: its sequence-preferential DNA binding creates a practical bridge between organoid structure, cell-cycle state, and assay reproducibility. This article connects the mechanistic properties of 4',6-diamidino-2-phenylindole hydrochloride with pancreatic ductal organoid development and offers a translational framework for selecting, validating, and deploying the reagent.

• Fosinopril Sodium in Cardiovascular Research

  2026-10-01

  Fosinopril sodium offers a practical ACE inhibition workflow for hypertension research, vascular assays, and renal hemodynamics studies. This guide connects its 9 nM ACE-inhibition benchmark with concentration planning, prodrug-aware controls, formulation troubleshooting, and the endpoint discipline used in contemporary cardiovascular trials.

• Y-27632 and the Logic of Translational ROCK Inhibition

  2026-10-01

  Y-27632 dihydrochloride offers a selective, reversible way to interrogate ROCK-dependent cytoskeletal phenotypes. This thought-leadership analysis connects its use as a ROCK inhibitor with emerging evidence that APOBEC3A, IL-1α, and AP-1 shape squamous differentiation in bladder cancer, while clearly separating established biology from testable translational hypotheses.

• Defactinib: FAK Phosphorylation Workflow

  2026-09-30

  Build a target-engagement workflow around Defactinib by pairing FAK Tyr397 phosphorylation measurements with viability, invasion, and paclitaxel-response endpoints. This practical framework helps distinguish pathway inhibition from nonspecific toxicity in ovarian cancer research and broader cancer therapy research.

• 1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  2026-09-29

  PP 3 is a research use only chemical that provides a concentration-matched negative-control arm for PP 2 experiments rather than another pathway inhibitor. This workflow applies ROS–calcium signaling findings from a vascular study to distinguish Src-associated interpretations from downstream L-type calcium-channel effects.

• Selective Spectrophotometry of Phenolic β-Lactams

  2026-09-29

  Salem and Saleh developed two selective spectrophotometric procedures for measuring four phenolic β-lactam antibiotics after oxidation with Ce(IV) or Fe(III) in acidic medium. The methods produced a shared yellow chromophore, enabling routine analysis of pure drugs and pharmaceutical formulations without relying on automated chromatographic systems.

• Fasudil (HA-1077) HCl: ROCK Translation

  2026-09-28

  A translational framework for using Fasudil (HA-1077) HCl as a ROCK inhibitor while connecting Rho/ROCK pathway inhibition with the pathway-validation logic emerging from Hippo signaling research in cataract models.

• Thiazovivin (A5506): Practical ROCK Inhibitor Guide

  2026-09-28

  Thiazovivin is a ROCK inhibitor used in workflows where researchers need to support fibroblast reprogramming or human embryonic stem cell survival after trypsinization. This guide covers product handling and experimental setup while distinguishing dossier specifications from protocol variables that must be established for each cell model; it is for research use, not clinical or diagnostic use.

• DDX21–NAT10 Signaling Drives CRC Metastasis

  2026-09-27

  A 2025 study links DDX21 to colorectal cancer metastasis and angiogenesis through competitive binding with SIRT7, transcriptional activation of NAT10, and increased ac4C modification of selected mRNAs. The findings identify a connected protein–chromatin–RNA stability pathway, while leaving its clinical and model-specific relevance to be established in further studies.

• Cordycepin–PDT Triggers Pyroptosis in Breast Cancer Cells

  2026-09-26

  A 2026 pre-proof study reports that cordycepin combined with photodynamic therapy (PDT) suppresses breast cancer cell growth and promotes pyroptosis associated with ROS accumulation, NLRP3 signaling, caspase-1, and GSDMD. Its inhibitor experiments support a role for oxidative stress and caspase-1, while leaving important questions about treatment parameters, pathway specificity, and in vivo relevance for follow-up studies.

• Morin in Bench Research: Workflows and Use Cases

  2026-09-26

  Use Morin to investigate oxidative stress, inflammation, podocyte energy metabolism, and aluminum-dependent fluorescence in controlled bench assays. A practical workflow pairs careful DMSO handling with orthogonal biological readouts—and keeps a clinical neuroleptic malignant syndrome case in its proper role as a lesson in measurement, not evidence of Morin treatment.

• Influenza Hemagglutinin (HA) Peptide in IP Workflows

  2026-09-25

  Use this competitive HA tag peptide to release HA-tagged proteins from antibody-based immunoprecipitation while preserving a route to analyze interaction partners. A practical workflow connects the peptide’s elution role to gastric-cancer signaling studies, with pilot parameters and troubleshooting guidance clearly distinguished from published findings.

• G418 Sulfate for RCC Cell Engineering

  2026-09-25

  Use Geneticin to establish and maintain neomycin-resistant renal cancer models for controlled studies of TFEB and PD-L1. This workflow connects reliable antibiotic selection with the key experimental questions raised by research on mTOR inhibitor resistance—without confusing selection with the tumor biology being tested.

• miR-18a–ALOXE3 Axis in Glioblastoma

  2026-09-24

  The study identifies ALOXE3 as a suppressor of glioblastoma growth, linking its loss to both resistance to p53–SLC7A11-dependent ferroptosis and increased migration. It further places miR-18a upstream of ALOXE3 and connects ALOXE3 silencing to 12-HETE-driven signaling, suggesting that lipid metabolism can influence distinct malignant traits in GBM.

8769 records 2/585 page Previous Next 12345 下5页 Last page